Kathleen A. Dorritie
Experienced in Monoclonal Gammopathy of Undetermined Significance (MGUS)
Experienced in Monoclonal Gammopathy of Undetermined Significance (MGUS)
5115 Centre Avenue, Hillman Cancer Center, 
Pittsburgh, PA 

Overview

Kathleen Dorritie, MD, is a hematologist/medical oncologist at UPMC Hillman Cancer Center specializing in hematologic malignancies and stem cell transplantation. Her research focuses on early phase clinical trials for lymphoid malignancies. She has been very involved in the development of the CAR T-cell program at UPMC and has also worked to develop a stem cell transplant program for hemoglobinopathies, including sickle cell disease.

Dr. Dorritie is rated as an Experienced provider by MediFind in the treatment of Monoclonal Gammopathy of Undetermined Significance (MGUS). Her top areas of expertise are Non-Hodgkin Lymphoma, Acute Myeloid Leukemia (AML), B-Cell Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant.

Her clinical research consists of co-authoring 38 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
SUNY Upstate Medical University
Residency
University of Pittsburgh School of Medicine
Specialties
Hematology Oncology
Licenses
Internal Medicine in PA
Board Certifications
American Board Of Internal Medicine
American Board Of Internal Medicine
Fellowships
University of Pittsburgh School of Medicine
Hospital Affiliations
Magee Womens Hospital Of Upmc Health System
Upmc Presbyterian Shadyside
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Avalon Health Care
  • MEDICARE PDP
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Gateway Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • OTHER MEDICARE PART D
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
PA Health and Wellness
  • HMO
  • MANAGED MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

UPMC Hillman Cancer Center
5115 Centre Avenue, Hillman Cancer Center, Pittsburgh, PA 15232

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


13 Clinical Trials

A Phase III Randomized Trial of Steroids + Tyrosine Kinase Inhibitor (TKI) Induction With Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL) in Adults
A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (iNHL)
A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7)
View 10 Less Clinical Trials
Similar Doctors
Sajid M. Peracha
Distinguished in Monoclonal Gammopathy of Undetermined Significance (MGUS)
Hematology Oncology
Distinguished in Monoclonal Gammopathy of Undetermined Significance (MGUS)
Hematology Oncology

UPMC Hillman Cancer Center

103 Transit Drive, 
Uniontown, PA 
 (39.7 miles away)
Languages Spoken:
English, Urdu
Accepting New Patients
Offers Telehealth

Sajid M. Peracha, MD, is a medical oncologist at UPMC Hillman Cancer Center, Uniontown. Dr. Peracha is board-certified in medical oncology, hematology, and internal medicine. He received his medical degree from Sind Medical College in Karachi, India. He completed his residency at Woodhull Medical and Mental Health Center in Brooklyn, N.Y., a fellowship at New York Medical College in Valhalla, N.Y., and bone marrow transplant training at the University of Florida in Gainesville, Fla. Dr. Peracha is rated as a Distinguished provider by MediFind in the treatment of Monoclonal Gammopathy of Undetermined Significance (MGUS). His top areas of expertise are Inflammatory Breast Cancer, Paget Disease of the Breast, Monoclonal Gammopathy of Undetermined Significance (MGUS), and Anemia.

Nishant Tageja
Advanced in Monoclonal Gammopathy of Undetermined Significance (MGUS)
Hematology Oncology
Advanced in Monoclonal Gammopathy of Undetermined Significance (MGUS)
Hematology Oncology

UPMC Hillman Cancer Center

400 Oxford Drive, Suite 102, 
Monroeville, PA 
 (9.7 miles away)
Languages Spoken:
English
Accepting New Patients
Offers Telehealth

Nishant Tageja, MD, is a medical oncologist and hematologist. Dr. Tageja specializes in the treatment of solid tumors such as breast cancer, lung cancer, and colon cancer as well as treatment of all benign and malignant blood disorders including lymphoma, leukemia, and myeloma. Dr. Tageja is rated as a Distinguished provider by MediFind in the treatment of Monoclonal Gammopathy of Undetermined Significance (MGUS). His top areas of expertise are Smoldering Multiple Myeloma, Non-Hodgkin Lymphoma, Familial Colorectal Cancer, Monoclonal Gammopathy of Undetermined Significance (MGUS), and Bone Marrow Transplant.

John K. Waas
Advanced in Monoclonal Gammopathy of Undetermined Significance (MGUS)
Hematology Oncology
Advanced in Monoclonal Gammopathy of Undetermined Significance (MGUS)
Hematology Oncology

UPMC Hillman Cancer Center, Independence Health System

8775 Norwin Avenue, Suite J, 
North Huntingdon, PA 
 (14.9 miles away)
Languages Spoken:
English
Accepting New Patients

John K. Waas, DO, is a medical oncologist at UPMC Hillman Cancer Center who practices at Arnold Palmer Medical Oncology at Norwin. Board-certified in medical oncology, Dr. Waas received his medical degree from Philadelphia College of Osteopathic Medicine in Philadelphia. He completed his residency at Lehigh Valley Hospital Center in Allentown, Pa. Dr. Waas is rated as a Distinguished provider by MediFind in the treatment of Monoclonal Gammopathy of Undetermined Significance (MGUS). His top areas of expertise are Protein C Deficiency, Protein S Deficiency, Congenital Antithrombin 3 Deficiency, and Hereditary Resistance to Anti-Vitamin K.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Dorritie's expertise for a condition
ConditionClose
    View All 13 Advanced Conditions
    View All 21 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile